ArticleAmerican journal of cardiovascular disease2025
Understanding the prevalence, in-hospital mortality and readmission rates amongst pulmonary vs cardiac sarcoidosis patients: insights from a nationwide registry.
Article in American journal of cardiovascular disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSarcoidosis is a multisystem granulomatous disorder, with pulmonary sarcoidosis (PS) affecting approximately 90% of patients and cardiac sarcoidosis (CS) being less common but associated with severe clinical implications. While PS is primarily characterized by respiratory symptoms, CS can lead to serious complications like heart failure and arrhythmias, contributing to sarcoidosis-related mortality. This study aims to compare the prevalence, in-hospital mortality, 30-day readmission rates, and healthcare costs between PS and CS patients using data from the Nationwide Readmissions Database (NRD).
methodsData were extracted from the NRD for adult patients diagnosed with PS or CS from January 2016 to December 2020. Baseline demographics, comorbidities, in-hospital outcomes, and 30-day readmission rates were analyzed. Statistical comparisons were made using appropriate tests for categorical and continuous variables.
resultsAmong 101,365 patients, 96,905 had PS and 4,460 had CS. CS patients experienced significantly higher rates of cardiovascular complications, such as heart failure (77.1% vs. 31.1%) and arrhythmias (75.8% vs. 27.7%), and incurred higher hospital charges ($59,520 vs. $40,249; P < 0.001). In-hospital mortality was similar between groups (CS: 2.4% vs. PS: 2.8%; P = 0.090). The 30-day readmission rate was comparable (CS: 12.9% vs. PS: 11.9%; P = 0.400), but PS patients were more likely to be readmitted for respiratory complications, while CS patients were readmitted primarily for heart failure.
conclusionsThis study underscores the distinct clinical profiles of PS and CS. Although CS is less prevalent, it is associated with a higher cardiovascular burden and healthcare costs. Both groups exhibited similar mortality and readmission rates, though their readmission causes differed. These findings highlight the need for targeted management strategies for PS and CS to optimize patient outcomes and resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.